Kalaris Therapeutics, Inc. (KLRS): restructuring charge — AlloVir reduces workforce by ~95%; expects $13M in severance charges

Kalaris Therapeutics, Inc.

Board approved cutting ~95% of employees to preserve capital after discontinuing three global Phase 3 posoleucel studies (announced Dec 22, 2023).
Reduction primarily in Q1 2024, substantially complete by April 15, 2024.
Expects ~$13M in personnel-related restructuring charges (severance and benefits) largely incurred in Q1 2024.
Additional charges may arise from retention efforts or other events.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Kalaris Therapeutics, Inc. announced a restructuring with charges of approximately $13 million (approximately 95% of AlloVir’s current employee base).

Type: restructuring
Charge: approximately $13 million
Headcount: approximately 95% of AlloVir’s current employee base

Exact text from the filing

2024 and expects to be substantially completed by April 15, 2024. As a result of these actions, AlloVir expects to incur personnel-related restructuring charges of approximately $13 million in connection with one-time employee termination cash expenditures, including severance and other benefits, which are expected to be substantially incurred in the first quarter

View on SEC.gov

7 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Kalaris Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-002563

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.